Dennis Stone - Reata Pharmaceuticals Director
| RETADelisted Stock | USD 172.36 0.02 0.01% |
Director
Dr. Dennis Stone, M.D. is Director of the Company. Since September 2002. Dr. Stone is Chief Scientific Officer of Remeditex Ventures LLC. He joined Remeditex in August 2011 from UT Southwestern Medical Center, or UTSW, where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development for UTSW from 1998 until July 2011. Dr. Stone has served on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., and MacroGenics, Inc. In addition, he served as the Chairman of the UT Regents Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Funds Life Science Commercialization Center. since 2002.
| Age | 63 |
| Tenure | 22 years |
| Phone | 972 865 2219 |
| Web | https://www.reatapharma.com |
Reata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 119.46 M in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Reata Pharmaceuticals has a current ratio of 10.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Reata Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Reata Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Reata Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Reata to invest in growth at high rates of return. When we think about Reata Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Southwell | PTC Therapeutics | 57 | |
| Scott Morenstein | Madrigal Pharmaceuticals | 38 | |
| Donald Kufe | Madrigal Pharmaceuticals | 69 | |
| Hans Wigzell | Sarepta Therapeutics | 79 | |
| Charles Rowland | Viking Therapeutics | 59 | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| William Reardon | Madrigal Pharmaceuticals | 68 | |
| JeanPaul Kress | Sarepta Therapeutics | 49 | |
| Dawn Svoronos | PTC Therapeutics | 71 | |
| Glenn Steele | PTC Therapeutics | 73 | |
| Richard Barry | Sarepta Therapeutics | 59 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Robert Wilson | Madrigal Pharmaceuticals | 75 | |
| Lawson Macartney | Viking Therapeutics | 60 | |
| Kathleen Behrens | Sarepta Therapeutics | 65 | |
| Anthony Chase | Sarepta Therapeutics | 60 | |
| Stephanie Okey | PTC Therapeutics | 58 | |
| Adam Koppel | PTC Therapeutics | 45 | |
| Paul Friedman | Madrigal Pharmaceuticals | 75 | |
| Mary Gray | Sarepta Therapeutics | 65 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
Management Performance
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 |
Reata Pharmaceuticals Leadership Team
Elected by the shareholders, the Reata Pharmaceuticals' board of directors comprises two types of representatives: Reata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reata. The board's role is to monitor Reata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren Huff, Chairman of the Board and Presidentident, CEO | ||
| Bhaskar Anand, VP Officer | ||
| Jack Nielsen, Independent Director | ||
| William Rose, Independent Director | ||
| Dawn Bir, Chief Commercial Officer | ||
| James Bass, Independent Director | ||
| Manmeet Soni, CFO COO | ||
| Steve Harman, VP Officer | ||
| Keith Ward, Vice President Chief Development Officer | ||
| Colin Meyer, Chief Medical Officer and Vice President Product Development | ||
| Christian Wigley, VP Officer | ||
| William McClellan, Director | ||
| Michael Wortley, Vice President Chief Legal Officer | ||
| Colin MD, Ex Officer | ||
| Vineet Jindal, Vice President Strategy & Analytics | ||
| Jason Wilson, CFO and Vice President Strategy | ||
| Elaine Castellanos, Consultant | ||
| Dennis Stone, Director | ||
| Dakota Gallivan, VP Officer | ||
| Kent McGaughy, Independent Director |
Reata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Reata Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Reata Pharmaceuticals' short interest history, or implied volatility extrapolated from Reata Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |